Proactiveinvestors recommends
Additional Information
Market: NASDAQ TSX-V
Sector: Pharmaceuticals
EPIC: NEPT
Latest Price: 2.93  (0.69% Ascending)
52-week High: 4.44
52-week Low: 2.05
Market Cap: 144.88M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Neptune Technologies & Bioressources
www.neptunebiotech.com

Neptune Technologies & Bioressources is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets.

 

Full Neptune Technologies & Bioressources profile here
Pdf

Health Canada approves claims for Neptune Technologies' krill oil supplement

29th Sep 2010, 3:49 pm
Health Canada approves claims for Neptune Technologies' krill oil supplement

Neptune Technologies & Bioressources (Nasdaq:NEPT) (TSX-V:NTB) announced Wednesday that Health Canada has approved therapeutic claims for Neptune Krill Oil (NKO), proving that the supplement is in fact safe and effective on certain diseases.

"Health claims are becoming among the most important drivers influencing the purchasing of Omega-3 supplements worldwide," said CFO Andre Godin.

If this is indeed true, then NKO supplements will see a jump in sales, as evidence reviewed by Health Canada has led to the approval of the product for a number of health claims including cardiovascular health, inflammation and women's health.

It was shown that NKO, in conjunction with other therapy, helps reduce the levels of harmful LDL cholesterol and increase the levels of beneficial HDL cholesterol, as well as helps reduce the levels of triglycerides in the body, with between only 2-4 softgels per day.

The supplement also demonstrated that it helps reduce pain associated with osteoarthritis and relieves pre-menstrual symptoms.

The Health Canada review process is considered one of the most rigorous in the world, as it involves an extensive assessment of the accuracy, validity and evidence supporting the proposed health claims.

In June last year, Health Canada approved health claims for omega-3, among which was the claim that products providing 3-10g of fish oil per day, or 6-20 softgels help to reduce serum triglycerides, compared to 4 NKO softgels recently approved for the same indication.

"The NKO approved claims are competitive when compared to the already approved claims for fish oils since not only have they been accepted at significantly much lower doses, but they also offer more specific health benefits in cardiovascular, joint and women health," said  Godin.

"This strategic milestone is expected to have a positive effect on sales because it fulfills new consumer requirements," he added.

Neptune formulates and produces phospholipid products for the nutraceutical and pharmaceutical markets. The company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases.

The company rallied 4% on the news, to trade at  $2.07 as of 10:48am on Wednesday morning.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.